SI-BONE to Present at the Morgan Stanley Global Healthcare Conference
SANTA CLARA, Calif. — SI-BONE, Inc. (Nasdaq: SIBN), a prominent medical device company focused on sacropelvic disorders, has announced its participation in the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference. Management will host a fireside chat during this significant event.
Event Details
The conference is scheduled for a specific date at 10:45 a.m. Eastern Time / 7:45 a.m. Pacific Time. This event provides SI-BONE with a valuable opportunity to engage with investors and share insights on the latest advancements in their product offerings, along with updates on treatments for sacropelvic disorders.
About SI-BONE, Inc.
SI-BONE, Inc. (NASDAQ: SIBN) has established itself as a leader in developing innovative technologies for the surgical treatment of sacropelvic disorders. The company pioneered minimally invasive sacroiliac joint surgery in 2009 and has since supported over 3,900 physicians in conducting more than 100,000 surgical procedures.
Clinical Evidence and Innovations
A strong foundation of clinical evidence supports the effectiveness of SI-BONE’s technologies. This includes two randomized controlled trials and over 130 peer-reviewed publications, which enhance the company's credibility in the medical field. SI-BONE has effectively leveraged its expertise in minimally invasive techniques to develop new solutions that address various related markets, including adult deformity corrections, spinopelvic fixation, and pelvic trauma.
Commitment to Innovation
SI-BONE is dedicated to improving patient outcomes and expanding its range of products. The company actively seeks to meet complex medical needs, ensuring healthcare providers have access to innovative tools that enhance surgical effectiveness and efficiency. This dedication positions SI-BONE as a leader in orthopedic technology.
Future Prospects and Growth
The company’s ongoing research and development initiatives are designed to solidify its leadership in the market. With a focus on advancing minimally invasive surgical techniques, SI-BONE is continually exploring new product opportunities that could broaden its impact in therapeutic areas related to sacropelvic disorders.
Investor Relations
For potential investors and stakeholders looking for more detailed insights into SI-BONE, the company's dedicated investor relations team is available to provide information regarding their products, services, and corporate strategies.
Contact Information
For inquiries, please reach out to Saqib Iqbal via email at investors@si-bone.com. The company is committed to maintaining transparent communication with its investors and the healthcare community.
Frequently Asked Questions
What is the focus of SI-BONE, Inc.?
SI-BONE, Inc. specializes in developing surgical technologies aimed at treating sacropelvic disorders.
When is SI-BONE's session at the Morgan Stanley conference?
SI-BONE's fireside chat is scheduled for 10:45 a.m. Eastern Time on a specific date.
How many procedures has SI-BONE supported?
SI-BONE has assisted over 3,900 physicians in performing more than 100,000 surgical procedures.
What clinical evidence supports SI-BONE’s technologies?
SI-BONE's effectiveness is backed by two randomized controlled trials and over 130 peer-reviewed publications.
How can investors learn more about SI-BONE?
Investors can contact the investor relations team via email or visit the company’s website for more comprehensive information.
